GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gilead Sciences Inc (XTER:GIS) » Definitions » Cyclically Adjusted Book per Share

Gilead Sciences (XTER:GIS) Cyclically Adjusted Book per Share : €17.19 (As of Mar. 2025)


View and export this data going back to 1999. Start your Free Trial

What is Gilead Sciences Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Gilead Sciences's adjusted book value per share for the three months ended in Mar. 2025 was €14.237. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €17.19 for the trailing ten years ended in Mar. 2025.

During the past 12 months, Gilead Sciences's average Cyclically Adjusted Book Growth Rate was 3.10% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 8.40% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 11.10% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was 16.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Gilead Sciences was 29.80% per year. The lowest was 2.40% per year. And the median was 23.95% per year.

As of today (2025-05-29), Gilead Sciences's current stock price is €96.01. Gilead Sciences's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 was €17.19. Gilead Sciences's Cyclically Adjusted PB Ratio of today is 5.59.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Gilead Sciences was 27.10. The lowest was 3.56. And the median was 6.02.


Gilead Sciences Cyclically Adjusted Book per Share Historical Data

The historical data trend for Gilead Sciences's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gilead Sciences Cyclically Adjusted Book per Share Chart

Gilead Sciences Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.82 12.85 15.08 15.97 17.80

Gilead Sciences Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.75 16.97 16.39 17.80 17.19

Competitive Comparison of Gilead Sciences's Cyclically Adjusted Book per Share

For the Drug Manufacturers - General subindustry, Gilead Sciences's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gilead Sciences's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Gilead Sciences's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Gilead Sciences's Cyclically Adjusted PB Ratio falls into.


;
;

Gilead Sciences Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Gilead Sciences's adjusted Book Value per Share data for the three months ended in Mar. 2025 was:

Adj_Book= Book Value per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=14.237/134.9266*134.9266
=14.237

Current CPI (Mar. 2025) = 134.9266.

Gilead Sciences Quarterly Data

Book Value per Share CPI Adj_Book
201506 9.852 100.684 13.203
201509 10.708 100.392 14.392
201512 11.965 99.792 16.178
201603 8.925 100.470 11.986
201606 10.388 101.688 13.783
201609 11.369 101.861 15.060
201612 13.668 101.863 18.105
201703 14.623 102.862 19.181
201706 15.454 103.349 20.176
201709 15.949 104.136 20.665
201712 13.206 104.011 17.131
201803 12.846 105.290 16.462
201806 14.314 106.317 18.166
201809 15.141 106.507 19.181
201812 14.664 105.998 18.666
201903 15.249 107.251 19.184
201906 15.804 108.070 19.732
201909 14.778 108.329 18.406
201912 16.013 108.420 19.928
202003 15.926 108.902 19.732
202006 12.766 108.767 15.836
202009 11.820 109.815 14.523
202012 11.931 109.897 14.648
202103 12.695 111.754 15.327
202106 13.041 114.631 15.350
202109 14.541 115.734 16.952
202112 14.869 117.630 17.055
202203 14.417 121.301 16.036
202206 15.266 125.017 16.476
202209 16.979 125.227 18.294
202212 16.079 125.222 17.325
202303 15.714 127.348 16.649
202306 15.660 128.729 16.414
202309 16.766 129.860 17.420
202312 16.803 129.419 17.518
202403 12.940 131.776 13.249
202406 13.632 132.554 13.876
202409 13.359 133.029 13.550
202412 14.812 133.157 15.009
202503 14.237 134.927 14.237

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Gilead Sciences  (XTER:GIS) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Gilead Sciences's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=96.01/17.19
=5.59

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Gilead Sciences was 27.10. The lowest was 3.56. And the median was 6.02.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Gilead Sciences Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Gilead Sciences's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Gilead Sciences Business Description

Industry
Address
333 Lakeside Drive, Foster City, CA, USA, 94404
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).